Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.40
Bid: 3.30
Ask: 3.50
Change: -0.60 (-15.00%)
Spread: 0.20 (6.061%)
Open: 4.15
High: 4.35
Low: 3.30
Prev. Close: 4.00
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Immedia Picks COO Penney As Interim CEO

Fri, 01st May 2020 14:57

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Friday and not separately reported by Alliance News:

----------

Immedia Group PLC - multi-media content - Chief Operating Officer Ross Penney named interim chief executive, with immediate effect. Bruno Brookes steps down as CEO "to focus on his other interests". Penney joined Immedia in 2006 as part of its acquisition of Cube Music.

----------

Orosur Mining Inc - South American-focused gold developer - hires Brad George as non-executive director. George is a Perth, Australia-based geoscientist with experience in South America and West Africa.

----------

ValiRx PLC - clinical stage biotechnology - Plans to appoint Suzanne Dilly as a director. Dilly has been chief executive officer of subsidiary ValiSeek Ltd since 2014.

----------

Horizon Discovery Group PLC - gene editing and modulation - Hires Siddhartha Kadia as non-executive director, replacing Susan Galbraith, effective Thursday. Kadia was CEO of EAG Laboratories until its acquisition by Eurofins Scientific in 2017. Galbraith currently is head of Early Oncology at AstraZeneca PLC, leaving Horizon Discovery due to increased responsibilities there, Horizon said.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
5 Jan 2022 10:50

AIM WINNERS & LOSERS: AdvancedAdvT buys into M&C Saatchi

AIM WINNERS & LOSERS: AdvancedAdvT buys into M&C Saatchi

Read more
5 Jan 2022 09:21

ValiRx enters agreement and potential sub-license with TheoremRx

ValiRx enters agreement and potential sub-license with TheoremRx

Read more
20 Dec 2021 15:00

TRADING UPDATES: InnovaDerma sees profit return; ValiRx amends licence

TRADING UPDATES: InnovaDerma sees profit return; ValiRx amends licence

Read more
20 Dec 2021 12:17

ValiRx amends longstanding licence deal with Cancer Research Technology

(Sharecast News) - Cancer therapeutics developer ValiRx announced on Monday that it has amended and restated the licence for the VAL201 peptide held by the company from Cancer Research Technology (CRT) to enable a range of sub-licensing options.

Read more
2 Nov 2021 14:34

TRADING UPDATES: Custodian sells car showroom; Samarkand buys Napiers

TRADING UPDATES: Custodian sells car showroom; Samarkand buys Napiers

Read more
2 Nov 2021 09:57

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

Read more
16 Sep 2021 18:19

IN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment

IN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment

Read more
7 Sep 2021 15:05

EARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips

EARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips

Read more
6 Jul 2021 13:00

ValiRx adds three new patents in first half

(Sharecast News) - Clinical-stage drug development company ValiRx updated the market on its patent portfolio on Tuesday, reporting that it had continued to build its intellectual property position in the first half of the year.

Read more
27 May 2021 20:17

TRADING UPDATES: Brave Bison, Strix Group see strong performances

TRADING UPDATES: Brave Bison, Strix Group see strong performances

Read more
27 May 2021 13:54

ValiRx terminates peptide drug candidate deal

(Sharecast News) - Clinical-stage drug development company ValiRx announced on Thursday that it has ended its agreement over the evaluation of the 'KTH222' peptide as a drug candidate for treating patients with ovarian cancer.

Read more
20 May 2021 16:07

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
28 Apr 2021 15:30

EXECUTIVE CHANGES: Ex-Coca-Cola exec, Cafe Rouge founder for Deliveroo

EXECUTIVE CHANGES: Ex-Coca-Cola exec, Cafe Rouge founder for Deliveroo

Read more
27 Apr 2021 11:32

TRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost

TRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost

Read more
15 Feb 2021 16:04

Physiomics and ValiRx enter new collaboration deal

(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it announced on Monday, superseding the agreement between the two companies, which was announced in September 2011.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.